Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsZyduslifesciences

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Cadila, Sun TV, Eros Intl, VIP: Krish Subramanyam

      Krish Subramanyam of Altamount Capital is of the view that one can buy Cadila Healthcare, Sun TV, Eros International and VIP Industries.

    • Buy Cadila Healthcare, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cadila Healthcare.

    • Bull's Eye: Buy Eros, VIP Ind, Sun TV, UBL, sell HDIL, Ceat

      Vishal Malkan of malkansview.com is of the view that one may buy Ashok Leyland with a target of Rs 97.

    • Invest in Alembic Pharma, says Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one can invest in Alembic Pharma.

    • Prefer Cadila Healthcare: Neeraj Deewan

      Neeraj Deewan of Quantum Securities is of the view that one may prefer Cadila Healthcare.

    • Buy Ipca Labs, target Rs 800-810: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Ipca Labs for a target of Rs 800-810.

    • Like pharma, including Dishman, Cadila: Deepak Shenoy

      Deepak Shenoy, Founder of capitalmind.in likes the pharma space including Dishman Pharma and Cadila Healthcare.

    • Look at Dr Reddy's Labs, Aurobindo Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can look at Dr Reddy's Laboratories, Aurobindo Pharma and Cadila Healthcare from the pharma space.

    • Buy Cadila Healthcare, Marico: Rahul Shah

      Rahul Shah of Motilal Oswal recommends buying Cadila Healthcare and Marico.

    • Buy Cadila Healthcare, Adani Ports: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, Cadila Healthcare and Adani Ports are worth buying at least for a day trade.

    • Positive on Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.

    • Apollo Hospitals may test Rs 1460: Rahul Mohindar

      According to Rahul Mohindar of Viratechindia.com, Apollo Hospitals may test Rs 1460.

    • Prefer MindTree, Cadila, LIC Housing: Dipan Mehta

      Dipan Mehta, Member of BSE & NSE is of the view that one may prefer MindTree, Zensar Technologies, Cadila Healthcare and LIC Housing Finance.

    • Alembic, Marico qualify as today‘s A-list stocks

      CNBC-TV18's research team brings you the cherry-picked companies from among thousands of listed stocks, which stand out on their own fundamentals. Two worthy of an A-list stature are Alembic Pharma and Marico.

    • 2 A list stocks that stand out in profit, return parameters

      The companies mentioned in A-list are picks of CNBC-TV18's experts and not recommendations to buy.

    • Bull's Eye: Buy Federal Bk, India Cement, Jet Air, sell DLF

      Dharmesh Kant of India Nivesh Securities advises buying Jet Airways with a target of Rs 399.

    • Positive on pharma, like Aurobindo Pharma: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is extremely positive on the pharma industry but feels that Sun Pharma will underperform.

    • Overweight on pharma, private sector banks: Dipan Mehta

      Dipan Mehta - member at BSE & NSE maintains overweight position on pharma as well as private sector banks.

    • Buy Cadila Healthcare, says Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that one may buy Cadila Healthcare.

    • Prefer Glenmark Pharma, Cadila Healthcare: Anu Jain

      Anu Jain of IIFL Private Wealth Management prefers Glenmark Pharma and Cadila Healthcare from the pharma space.

    • Phani Sekhar positive on largecap pharma space

      Phani Sekhar, Fund Manager--PMS at Karvy Stock Broking has a positive view on largecap pharma space.

    • Prefer Cadila Healthcare, Wockhardt: Sanju Verma

      Sanju Verma of Violet Arc Global Managers is of the view that one may prefer Cadila Healthcare followed by Wockhardt and Cipla.

    • Hold Lupin, prefer Cadila, Aurobindo Pharma: Anand Tandon

      Market Expert, Anand Tandon is of the view that one may hold Lupin with long term view.

    • See 10-15% upside in midcap pharma space: Vineet Bhatnagar

      Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

    • Hold Cadila, Torrent Pharma, Infosys, TCS: Rajesh Kothari

      Rajesh Kothari, MD, AlfAccurate Advisors advises holding Cadila Healthcare, Torrent Pharma, Infosys, HCL Tech and TCS.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347